Telix Pharmaceuticals Faces Securities Lawsuit
Analysis based on 16 articles · First reported Dec 03, 2025 · Last updated Dec 23, 2025
The market is negatively impacted by the securities class action lawsuit against Telix Pharmaceuticals, as its stock price dropped significantly following regulatory setbacks. This event highlights the risks associated with undisclosed supply chain issues and overstated developmental progress in the pharmaceutical industry, potentially leading to increased scrutiny on similar companies.
Telix Pharmaceuticals is facing a securities class action lawsuit led by Hagens Berman, with a deadline for lead plaintiff appointment set for January 9, 2026. The lawsuit alleges that Telix Pharmaceuticals and its executives materially overstated the developmental progress of its therapeutic candidates, specifically TLX591 and TLX592, and misrepresented the reliability and regulatory compliance of its third-party supply chain and manufacturing partners. These allegations stem from two significant regulatory events: an SEC subpoena issued on July 22, 2025, concerning disclosures on drug development, and a devastating Complete Response Letter (CRL) from the United States — Food and Drug Administration on August 28, 2025, rejecting the Zircaix (TLX250-CDx) application due to fundamental Chemistry, Manufacturing, and Controls (CMC) and Form 483 deficiencies at third-party manufacturers. These regulatory setbacks led to a sharp 21% decline in Telix Pharmaceuticals' stock.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard